Period of time： 2003年8期
Publisher： Elsevier
Founded in： 1978
Total resources： 7
ISSN： 1359-6349
Subject： R73 Oncology
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
EJC Supplements,volume 1,issue 8
Menu
Access to resources
Recommend
Novel approaches in oncology at AstraZeneca
By Wheeler C., Stephens T., Byth K., Green T., Wedge S., Blakey D., Hughes A. in (2003)
EJC Supplements,volume 1,issue 8 , Vol. 1, Iss. 8, 2003-10 , pp.Targeting the epidermal growth factor receptor: prognostic and clinical implications
EJC Supplements,volume 1,issue 8 , Vol. 1, Iss. 8, 2003-10 , pp.Clinical benefit in NSCLC: the evidence for gefitinib ('Iressa', ZD1839)
EJC Supplements,volume 1,issue 8 , Vol. 1, Iss. 8, 2003-10 , pp.Symptoms and quality of life: important patient outcomes?
EJC Supplements,volume 1,issue 8 , Vol. 1, Iss. 8, 2003-10 , pp.Gefitinib ('Iressa', ZD1839): the patients' experience
EJC Supplements,volume 1,issue 8 , Vol. 1, Iss. 8, 2003-10 , pp.